Cynata Therapeutics

1233 High Street
Suite 1
Armadale
Victoria
3143

Tel: 61-0-412-119343

Website: http://cynata.com/

Show jobs for this employer

44 articles about Cynata Therapeutics

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers.

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease.

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers, up to the 10-week follow-up time point.

  • Cynata Therapeutics Limited is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.

  • Clinical Catch-Up: 3's the Charm for Pfizer-BioNTech Vaccine in Kids & More

    A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.

  • US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company.

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced that it has entered into a new strategic partnership agreement with Fujifilm Corporation.

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval by the Central Adelaide Local Health Network Human Research Ethics Committee to commence a clinical trial of Cynata’s Cymerus™ mesenchymal stem cell product in patients with diabetic foot ulcers.

  • Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company” ), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 million placement ( “Placement” ), led by a $10m investment from experienced healthcare investor BioScience Managers through the BioScience Managers Translation Fund I (BMTFI). BMTFI has a mandate to invest in Australian based innovative healthcare techn

  • Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that the Phase 3 SCUlpTOR (“Stem Cells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis”) Trial of CYP-004, Cynata’s Cymerus™ mesenchymal stem cell (MSC) product for osteoarthritis, has now commenced.

  • BioSpace Global Roundup, Sept. 10

    Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has announced positive efficacy data from a study of its induced pluripotent stem cell -derived Cymerus™ mesenchymal stem cells in a preclinical rodent model of idiopathic pulmonary fibrosis.

  • BioSpace Global Roundup, Aug. 27

    Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines.

  • Cynata Therapeutics Limited (ASX: CYP), a leading clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that the MEND (MEseNchymal coviD-19) Trial is now open for patient enrolment. Following ethics committee approval (as announced on 8 May 2020), this important step represents the formal commencement of this clinical trial.

  • Cynata Therapeutics Limited (ASX: “ CYP”, “Cynata”, or the “Company” ), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced positive results from the two-year follow-up of patients enrolled in the Phase 1 clinical trial of CYP-001, Cynata’s lead induced pluripotent stem cell (iPSC)-derived Cymerus™ mesenchymal stem cell (MSC) product. The Phase 1 trial, which was the world’s first clinical trial

  • Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to report important progress towards the commencement of recruitment in the Phase 3 clinical trial of CYP-004, its Cymerus™ mesenchymal stem cell (MSC) product for osteoarthritis

  • Cynata Therapeutics Limited (ASX: “ CYP”, “Cynata”, or the “Company” ), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19. In addition, the Company also provides updated gui

  • Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a scientific paper describing the use of Cymerus™ mesenchymal stem cells (MSCs) in a model of Acute Respiratory Distress Syndrome (ARDS) has been accepted for publication in the American Journal of Respiratory and Critical Care Medicine (AJRCCM). 1 The AJRCCM, commonly known as “ The Blue Journal

  • Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received an additional A$618,667 R&D Tax Incentive Refund for the 2018/2019 financial year and to provide a market update on other activities.

  • Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with its Phase 2 clinical trial of the Cymerus™ mesenchymal stem cell (MSC) product CYP-002 in patients with critical limb ischaemia (CLI).